Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis

Cancer Letters

Volumn 302, Issue 1, 2011, Pages 54-62

  Verbeke, Hannelien ^a   Struyf, Sofie ^a   Berghmans, Nele ^a   Van Coillie, Els ^a   Opdenakker, Ghislain ^a   Uyttenhove, Catherine ^b,c   Van Snick, Jacques ^b,c   Van Damme, Jo ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

Chemokine; Granulocyte chemotactic protein 2 (GCP 2); Melanoma

Indexed keywords

GRANULOCYTE CHEMOTACTIC PROTEIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4; MONOCLONAL ANTIBODY B5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL6; CHEMOTAXIS, LEUKOCYTE; FEMALE; GRANULOCYTES; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM METASTASIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 79251593489     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.013     Document Type: Article

References (52)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
2. Moser B., Willimann K. Chemokines: role in inflammation and immune surveillance. Ann. Rheum. Dis. 2004, 63(Suppl. 2):ii84-ii89.
3. Rot A., Von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004, 22:891-928.
4. Proost P., Wolf-Peeters C., Conings R., Opdenakker G., Billiau A., Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J. Immunol. 1993, 150:1000-1010.
5. Strieter R.M., Polverini P.J., Arenberg D.A., Kunkel S.L. The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4:155-160.
6. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008, 267:226-244.
7. Van Damme J., Wuyts A., Froyen G., Van Coillie E., Struyf S., Billiau A., Proost P., Wang J.M., Opdenakker G. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J. Leukocyte Biol. 1997, 62:563-569.
8. Zhu Y.M., Bagstaff S.M., Woll P.J. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer. Brit. J. Cancer 2006, 94:1936-1941.
9. Engl T., Relja B., Blumenberg C., Muller I., Ringel E.M., Beecken W.D., Jonas D., Blaheta R.A. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci. 2006, 78:1784-1793.
10. Bieche I., Chavey C., Andrieu C., Busson M., Vacher S., Le Corre L., Guinebretiere J.M., Burlinchon S., Lidereau R., Lazennec G. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr. Relat. Cancer 2007, 14:1039-1052.
11. Gijsbers K., Gouwy M., Struyf S., Wuyts A., Proost P., Opdenakker G., Penninckx F., Ectors N., Geboes K., Van Damme J. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp. Cell Res. 2005, 303:331-342.
12. Van Coillie E., Van Aelst I., Wuyts A., Vercauteren R., Devos R., Wolf-Peeters C., Van Damme J., Opdenakker G. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am. J. Pathol. 2001, 159:1405-1414.
13. Wuyts A., Struyf S., Gijsbers K., Schutyser E., Put W., Conings R., Lenaerts J.P., Geboes K., Opdenakker G., Menten P., Proost P., Van Damme J. The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1beta and is down-regulated by interferon-gamma: comparison with interleukin-8/CXCL8. Lab Invest. 2003, 83:23-34.
14. Fillmore R.A., Nelson S.E., Lausch R.N., Oakes J.E. Differential regulation of ENA-78 and GCP-2 gene expression in human corneal keratocytes and epithelial cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:3432-3437.
15. Gijsbers K., Van Assche G., Joossens S., Struyf S., Proost P., Rutgeerts P., Geboes K., Van Damme J. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur. J. Immunol. 2004, 34:1992-2000.
16. Collin M., Linge H.M., Bjartell A., Giwercman A., Malm J., Egesten A. Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. J. Reprod. Immunol. 2008, 79:37-43.
17. Thorburn E., Kolesar L., Brabcova E., Petrickova K., Petricek M., Jaresova M., Slavcev A., Striz I. CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS 2009, 117:477-487.
18. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278:8508-8515.
19. Wuyts A., Van Osselaer N., Haelens A., Samson I., Herdewijn P., Ben Baruch A., Oppenheim J.J., Proost P., Van Damme J. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 1997, 36:2716-2723.
20. Wolf M., Delgado M.B., Jones S.A., Dewald B., Clark-Lewis I., Baggiolini M. Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2. Eur. J. Immunol. 1998, 28:164-170.
21. Smith J.B., Herschman H.R. Glucocorticoid-attenuated response genes encode intercellular mediators, including a new C-X-C chemokine. J. Biol. Chem. 1995, 270:16756-16765.
22. Wuyts A., Haelens A., Proost P., Lenaerts J.P., Conings R., Opdenakker G., Van Damme J. Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J. Immunol. 1996, 157:1736-1743.
23. Wuyts A., D'Haese A., Cremers V., Menten P., Lenaerts J.P., De Loof A., Heremans H., Proost P., Van Damme J. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency. J. Immunol. 1999, 163:6155-6163.
24. Lee J., Cacalano G., Camerato T., Toy K., Moore M.W., Wood W.I. Chemokine binding and activities mediated by the mouse IL-8 receptor. J. Immunol. 1995, 155:2158-2164.
25. Fu W., Zhang Y., Zhang J., Chen W.F. Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1. Cytokine 2005, 31:9-17.
26. Fan X., Patera A.C., Pong-Kennedy A., Deno G., Gonsiorek W., Manfra D.J., Vassileva G., Zeng M., Jackson C., Sullivan L., Sharif-Rodriguez W., Opdenakker G., Van Damme J., Hedrick J.A., Lundell D., Lira S.A., Hipkin R.W. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J. Biol. Chem. 2007, 282:11658-11666.
27. Uyttenhove C., Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 2006, 36:2868-2874.
28. Uyttenhove C., Arendse B., Stroobant V., Brombacher F., Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 2004, 34:3572-3581.
29. Gouwy M., Struyf S., Catusse J., Proost P., Van Damme J. Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. J. Leukocyte Biol. 2004, 76:185-194.
30. Struyf S., Gouwy M., Dillen C., Proost P., Opdenakker G., Van Damme J. Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. Eur. J. Immunol. 2005, 35:1583-1591.
31. Struyf S., Proost P., Schols D., De Clercq E., Opdenakker G., Lenaerts J.P., Detheux M., Parmentier M., De Meester I., Scharpe S., Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 1999, 162:4903-4909.
32. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol. 2004, 14:155-160.
33. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:133-144.
34. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
35. Wallace M.E., Smyth M.J. The role of natural killer cells in tumor control - effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. 2005, 27:49-64.
36. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
37. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
38. Gabellini C., Trisciuoglio D., Desideri M., Candiloro A., Ragazzoni Y., Orlandi A., Zupi G., Del Bufalo D. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer. 2009, 45:2618-2627.
39. Wang B., Hendricks D.T., Wamunyokoli F., Parker M.I. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006, 66:3071-3077.
40. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Morris S.B., Xue Y.Y., Burdick M.D., Glass M.C., Iannettoni M.D., Strieter R.M. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 1998, 102:465-472.
41. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., Gudas J.M., Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002, 161:125-134.
42. Speetjens F.M., Kuppen P.J., Sandel M.H., Menon A.G., Burg D., van de Velde C.J., Tollenaar R.A., de Bont H.J., Nagelkerke J.F. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin. Cancer Res. 2008, 14:2276-2284.
43. Hirano S., Iwashita Y., Sasaki A., Kai S., Ohta M., Kitano S. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J. Gastroenterol. Hepatol. 2007, 22:690-696.
44. Varney M.L., Li A., Dave B.J., Bucana C.D., Johansson S.L., Singh R.K. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 2003, 20:723-731.
45. Varney M.L., Johansson S.L., Singh R.K. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 2006, 125:209-216.
46. Singh S., Sadanandam A., Varney M.L., Nannuru K.C., Singh R.K. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int. J. Cancer 2010, 126:328-336.
47. Nurnberg W., Tobias D., Otto F., Henz B.M., Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J. Pathol. 1999, 189:546-551.
48. Rofstad E.K., Mathiesen B., Henriksen K., Kindem K., Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res. 2005, 65:2387-2396.
49. Lev D.C., Ruiz M., Mills L., McGary E.C., Price J.E., Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther. 2003, 2:753-763.
50. Gebhardt C., Averbeck M., Viertel A., Kauer F., Saalbach A., Anderegg U., Simon J.C. Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp. Dermatol. 2007, 16:636-643.
51. Fujimori A., Okayasu R., Ishihara H., Yoshida S., Eguchi-Kasai K., Nojima K., Ebisawa S., Takahashi S. Extremely low dose ionizing radiation up-regulates CXC chemokines in normal human fibroblasts. Cancer Res. 2005, 65:10159-10163.
52. Xu L., Duda D.G., diTomaso E., Ancukiewicz M., Chung D.C., Lauwers G.Y., Samuel R., Shellito P., Czito B.G., Lin P.C., Poleski M., Bentley R., Clark J.W., Willett C.G., Jain R.K. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009, 69:7905-7910.